WATERTOWN, Mass, Sept. 12, 2017 -- For the eighth year in a row, pediatricians ranked the temporal artery thermometer (TAT) as the number one overall preferred method of thermometry, according to a recent survey. Of the 216 survey respondents, more than half (54 percent) of pediatricians chose temporal artery as their preferred method of thermometry based on ease of use. In addition, 41 percent cited temporal artery as the overall preferred method of thermometry compared to ear, rectal, oral and axillary, ranking the TAT number one in this category.
This new study demonstrates how the Exergen TemporalScanner remains, over time, the most trusted temporal artery thermometer brand and one of the top overall thermometer brands used and recommended in pediatrician offices. Survey findings show 39 percent of pediatricians use Exergen Temporal Artery Thermometer in their offices, and nearly 75 percent of those pediatricians recommend the Exergen brand to their patients and colleagues. The survey results also indicate that pediatricians use the Exergen TAT for a range of patient ages.
“Every year, these study results confirm that the Exergen TAT is the number one preferred by pediatricians for a variety of reasons, which include ease of use and noninvasive properties,” said Dr. Francesco Pompei, CEO of Exergen Corporation. “More and more pediatricians trust and rely on the TAT, whose accuracy and versatility is backed by more than 70 clinical studies. It offers great versatility, as well, and pediatricians are comfortable using our thermometer on all ranges of patient ages and medical conditions.”
The survey captured pediatricians’ commentary about temporal artery thermometry, specifically strengths of the Exergen TAT. One physician respondent noted, “I have used the Exergen [TAT] for many years – it is easy, quick and gives me the information I need.” Another respondent stated, “Temporal Artery is easiest to use – digital, oral and rectal [are] more time consuming and require patient cooperation.”
The survey was conducted by Pragmatic Research, Inc. and pediatricians were not told that it was sponsored by Exergen. The results were consistent with other independent research involving nurses and other healthcare professionals in various clinical settings.
ABOUT EXERGEN CORPORATION
Exergen manufactures and markets two types of the TemporalScanner thermometer: a professional version for doctors' offices and hospitals, and a consumer model sold in major retailers nationwide. Nearly two billion temperatures are taken each year with the TemporalScanner. It is used in thousands of hospitals, clinics and pediatricians' offices across the country, as well as in millions of homes. It is the #1 preference of pediatricians, #1 preference of nurses in the US, and #1 selling retail thermometer. The Exergen TemporalScanner's performance is supported by more than 70 peer-reviewed published studies covering all ages from preterm infants to geriatrics and all care areas from hospitals to homes. For additional information, visit www.exergen.com.
Contact: Victoria Day
Rosica Public Relations
[email protected]
P: 201.843.5600
F: 201.843.5680
21-00 Route 208 South, Suite 130
Fair Lawn, NJ 07410


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 



